己糖激酶2在NSCLC厄洛替尼耐药中的作用及机制

游启爱; 卓文磊; 陈正堂

doi:10.16016/j.1000-5404.201912141

您当前的位置：

首页 >

文章列表页 >

己糖激酶2在NSCLC厄洛替尼耐药中的作用及机制

基础医学 | 更新时间：2026-01-09

- 己糖激酶2在NSCLC厄洛替尼耐药中的作用及机制
- Role and mechanism of hexokinase 2 in erlotinib resistance in non-small cell lung cancer
- 第三军医大学学报 2020年42卷第5期页码：453-459
- 作者机构：
  
  400037 重庆，陆军军医大学(第三军医大学)第二附属医院全军肿瘤研究所
- 作者简介：
  
  [陈正堂，E-mail: czt05@163.comCHEN Zhengtang, E-mail: czt05@163.com
- 基金信息：
  
  国家自然科学基金面上项目(81672290);陆军军医大学人才库重点扶持项目(2019年)
- DOI：10.16016/j.1000-5404.201912141
  中图分类号： R345;R730.23;R737.9
- 收稿：2019-12-16，
  
  修回：2020-01-25，
  
  纸质出版：2020-03-15
- 稿件说明：
移动端阅览
游启爱, 卓文磊, 陈正堂. 己糖激酶2在NSCLC厄洛替尼耐药中的作用及机制[J]. 第三军医大学学报, 2020,42(5):453-459.

Qi YOU, Wenlei ZHUO, Zhengtang CHEN. Role and mechanism of hexokinase 2 in erlotinib resistance in non-small cell lung cancer[J]. Journal of Third Military Medical University, 2020, 42(5): 453-459.
游启爱, 卓文磊, 陈正堂. 己糖激酶2在NSCLC厄洛替尼耐药中的作用及机制[J]. 第三军医大学学报, 2020,42(5):453-459. DOI： 10.16016/j.1000-5404.201912141.

Qi YOU, Wenlei ZHUO, Zhengtang CHEN. Role and mechanism of hexokinase 2 in erlotinib resistance in non-small cell lung cancer[J]. Journal of Third Military Medical University, 2020, 42(5): 453-459. DOI： 10.16016/j.1000-5404.201912141.

摘要

目的

观察糖酵解关键酶己糖激酶2(hexokinase 2，HK2)在人非小细胞肺癌(non-small cell lung cancer

NSCLC)组织中的表达，探讨HK2在NSCLC厄洛替尼耐药中的作用及机制。

方法

在线数据库分析肺癌组织中HK2的表达与预后的关系以及厄洛替尼对NSCLC HK2基因表达的影响；q-PCR体外验证HK2在正常肺上皮细胞、肺癌细胞中的表达差异；q-PCR、Western blot检测厄洛替尼敏感细胞(PC9)、耐药细胞(PC9/ER)中HK2的基础表达以及厄洛替尼干预后HK2的表达情况；进而使用HK2抑制剂3-溴丙酮酸处理PC9/ER，采用CCK-8法检测PC9/ER耐药性、流式细胞术分析PC9/ER的增殖能力。

结果

HK2与肺癌患者预后不良相关，HK2高表达组患者的总体生存期(overall survival

OS)较低表达组明显缩短(

0.05)；细胞实验证实HK2在PC9/ER中相对高表达，且厄洛替尼可降低PC9细胞中HK2的表达，而对PC9/ER细胞HK2的表达无显著影响；3-溴丙酮酸可有效抑制PC9/ER中HK2的表达，CCK-8法结果表明，PC9/ER 3-溴丙酮酸处理组厄洛替尼IC

值较PC9/ER对照组显著降低，提示3-溴丙酮酸处理后能让耐药的PC9/ER细胞恢复对厄洛替尼的敏感性；3-溴丙酮酸处理组增殖指数为(14.1±0.8)%，较对照组(30.4±2.3)%显著减少(

=0.008)，提示3-溴丙酮酸能明显抑制耐药细胞增殖。

结论

HK2是NSCLC患者的不良预后指标，可诱导NSCLC厄洛替尼耐药。可能和其促进糖酵解的机制有关，抑制其表达有望成为逆转NSCLC厄洛替尼耐药的有效策略。

Abstract

Objective

To observe the expression of hexokinase 2 (HK2)

a key enzyme of glycolysis

in human non-small cell lung cancer (NSCLC) tissues

and to investigate the role and mechanism of HK2 in the resistance of NSCLC to erlotinib.

Methods

The relationship between the expression of HK2 and prognosis in lung cancer and the effect of erlotinib on NSCLC HK2 gene exlpression were analyzed through online databases (Kaplan-Meier Plotter

GEPIA and GEO DataSets). q-PCR was used to verify the expression differences of HK2 in normal lung epithelial cells and lung cancer cells

in vitro

. The basic expression of HK2 in erlotinib-sensitive cells (PC9) and erlotinib-resistant cells (PC9/ER) and the expression of HK2 after erlotinib intervention were detected by q-PCR and Western blotting. After 3-bromopyruvate

a HK2 inhibitor

was used to treat PC9/

ER cells

the erlotinib resistance and cell proliferation in PC9/ER cells were detected by CCK-8 assay and flow cytometry.

Results

HK2 was associated with poor prognosis in NSCLC patients

and overall survival (OS) in the group with high expression of HK2 was significantly shortened when compared with the group with low expression (

0.05). Cell experiments confirmed that HK2 was relatively highly expressed in PC9/ER cells

and erlotinib treatment could reduce HK2 expression in PC9 cells

but had no significant effect on PC9/ER cells. 3-bromopyruvate successfully inhibited the expression of HK2 in PC9/ER cells. CCK-8 assay showed that IC

value of erlotinib was significantly lower in the PC9/ER 3-bromopyruvate treated group than the PC9/ER control group (0.005±0.001

1.967±0.436 μmol/L

=0.016)

suggesting that the inhibitor treatment can restore the sensitivity of PC9/ER cells to erlotinib. In addition

the treatment also resulted in significantly decreased proliferation index in the 3-bromopyruvate treatment group than the control group [(14.1±0.8)%

(30.4±2.3)%

=0.008)

indicating that the inhibitor could significantly inhibit the proliferation of drug-resistant cells.

Conclusion

HK2 is an indicator for poor prognosis in NSCLC patients. It can induce erlotinib resistance to NSCLC

which may be associated with its promotion in glycolysis

and inhibiting its expression may be an effective strategy to reverse erlotinib resistance in NSCLC.

关键词

Keywords

references

TORRE L A, BRAY F, SIEGEL R L, et al . Global cancer statistics, 2012[J ] . CA Cancer J Clin, 2015, 65(2): 87-108. DOI:10.3322/caac.21262.

BRAY F, FERLAY J, SOERJOMATARAM I, et al . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J ] . CA Cancer J Clin, 2018, 68(6): 394-424. DOI:10.3322/caac.21492.

ROSELL R, CARCERENY E, GERVAIS R, et al . Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial[J ] . Lancet Oncol, 2012, 13(3): 239-246. DOI:10.1016/S1470-2045(11)70393-X.

WU Y L, ZHOU C, LIAM C K, et al . First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase Ⅲ, randomized, open-label, ENSURE study[J ] . Ann Oncol, 2015, 26(9): 1883-1889. DOI:10.1093/annonc/mdv270.

NEEL D S, BIVONA T G. Resistance is futile: overcoming resistance to targeted therapies in lung adenocarcinoma[J]. NPJ Precis Oncol, 2017, 1: 3. DOI:10.1038/s41698-017-0007-0.

CHABON J J, SIMMONS A D, LOVEJOY A F, et al . Corrigendum: Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients[J ] . Nat Commun, 2016, 7: 13513. DOI:10.1038/ncomms13513.

YU H A, ARCILA M E, REKHTMAN N, et al . Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers[J ] . Clin Cancer Res, 2013, 19(8): 2240-2247. DOI:10.1158/1078-0432.CCR-12-2246.

LIBERTI M V, LOCASALE J W. The Warburg effect: how does it benefit cancer cells?[J]. Trends Biochem Sci, 2016, 41(3): 211-218. DOI:10.1016/j.tibs.2015.12.001.

PAVLOVA N N, THOMPSON C B. The emerging hallmarks of cancer metabolism[J]. Cell Metab, 2016, 23(1): 27-47. DOI:10.1016/j.cmet.2015.12.006.

WANG H, SHEEHAN R P, PALMER A C, et al . Adaptation of human iPSC-derived cardiomyocytes to tyrosine kinase inhibitors reduces acute cardiotoxicity via metabolic reprogramming[J ] . Cell Syst, 2019, 8(5): 412-426.e7. DOI:10.1016/j.cels.2019.03.009.

ROBERTS D J, MIYAMOTO S. Hexokinase Ⅱ integrates energy metabolism and cellular protection: Akting on mitochondria and TORCing to autophagy[J]. Cell Death Differ, 2015, 22(2): 364. DOI:10.1038/cdd.2014.208

DEWAAL D, NOGUEIRA V, TERRY A R, et al . Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin[J ] . Nat Commun, 2018, 9(1): 446. DOI:10.1038/s41467-017-02733-4.

LEE H J, LI C F, RUAN D, et al . Non-proteolytic ubiquitination of hexokinase 2 by HectH9 controls tumor metabolism and cancer stem cell expansion[J ] . Nat Commun, 2019, 10(1): 2625. DOI:10.1038/s41467-019-10374-y.

WANG L, WANG J, XIONG H, et al . Co-targeting hexokinase 2-mediated Warburg effect and ULK1-dependent autophagy suppresses tumor growth of PTEN- and TP53-deficiency-driven castration-resistant prostate cancer[J ] . EBio Medicine, 2016, 7: 50-61. DOI:10.1016/j.ebiom.2016.03.022.

ZHOU L, LI M, YU X Y, et al . Repression of hexokinases Ⅱ-mediated glycolysis contributes to piperlongumine-induced tumor suppression in non-small cell lung cancer cells[J ] . Int J Biol Sci, 2019, 15(4): 826-837. DOI:10.7150/ijbs.31749.

LIS P, DYLAG M, NIEDZWIECKA K, et al . The HK2 dependent "Warburg effect" and mitochondrial oxidative phosphorylation in cancer: targets for effective therapy with 3-bromopyruvate[J ] . Molecules, 2016, 21(12): E1730. DOI:10.3390/molecules21121730.

JIAO L, ZHANG H L, LI D D, et al . Regulation of glycolytic metabolism by autophagy in liver cancer involves selective autophagic degradation of HK2 (hexokinase 2)[J ] . Autophagy, 2018, 14(4): 671-684. DOI:10.1080/15548627.2017.1381804.

WOLF A, AGNIHOTRI S, MICALLEF J, et al . Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme[J ] . J Exp Med, 2011, 208(2):313-326. DOI:10.1084/jem.20101470.

GUO W, QIU Z, WANG Z, et al . MiR-199a-5p is negatively associated with malignancies and regulates glycolysis and lactate production by targeting hexokinase 2 in liver cancer[J ] . Hepatology, 2015, 62(4):1132-1144. DOI: 10.1002/hep.27929.

KWIATKOWSKA E, WOJTALA M, GAJEWSKA A, et al . Effect of 3-bromopyruvate acid on the redox equilibrium in non-invasive MCF-7 and invasive MDA-MB-231 breast cancer cells[J ] . J Bioenerg Biomembr, 2016, 48(1): 23-32. DOI:10.1007/s10863-015-9637-5.

SUN Y M, LIU Z, ZOU X, et al . Mechanisms underlying 3-bromopyruvate-induced cell death in colon cancer[J ] . J Bioenerg Biomembr, 2015, 47(4): 319-329. DOI:10.1007/s10863-015-9612-1.

AKINS N S, NIELSON T C, LE H V. Inhibition of glycolysis and glutaminolysis: an emerging drug discovery approach to combat cancer[J]. Curr Top Med Chem, 2018, 18(6): 494-504. DOI:10.2174/1568026618666180523111351.

PILLAI S R, DAMAGHI M, MARUNAKA Y, et al . Causes, consequences, and therapy of tumors acidosis[J ] . Cancer Metastasis Rev, 2019, 38(1/2): 205-222. DOI:10.1007/s10555-019-09792-7.

GILLIES R J, VERDUZCO D, GATENBY R A. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work[J]. Nat Rev Cancer, 2012, 12(7): 487-493. DOI:10.1038/nrc3298.

ZHANG M, CONG Q, ZHANG X Y, et al . Pyruvate dehydrogenase kinase 1 contributes to cisplatin resistance of ovarian cancer through EGFR activation[J ] . J Cell Physiol, 2 019, 234(5): 6361-6370. DOI:10.1002/jcp.27369.

ICARD P, SHULMAN S, FARHAT D, et al . How the Warburg effect supports aggressiveness and drug resistance of cancer cells?[J ] . Drug Resist Updat, 2018, 38: 1-11. DOI:10.1016/j.drup.2018.03.001.

ZHANG Q W, ZHANG Y Y, ZHANG P, et al . Hexokinase Ⅱ inhibitor, 3-BrPA induced autophagy by stimulating ROS formation in human breast cancer cells[J ] . Genes Cancer, 2014, 5(3/4): 100-112. DOI:10.18632/genesandcancer.9.

ZHOU P, CHEN W G, LI X W. MicroRNA-143 acts as a tumor suppressor by targeting hexokinase 2 in human prostate cancer[J]. Am J Cancer Res, 2015, 5(6): 2056-2063.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

Rab25在非小细胞肺癌厄洛替尼获得性耐药中的作用

晚期非小细胞肺癌患者血清细胞因子IL-1β、IL-2R、IL-6及TNF-α水平与厄洛替尼疗效的相关性研究

融合深度学习、临床与影像组学特征的综合模型提升非小细胞肺癌EGFR突变预测效能

DLGAP5通过调控Warburg效应促进口腔鳞状细胞癌的进展